

The Effects of Clofibrate on Neonatal Jaundice: A Systematic Review

Abstract

Background: Neonatal jaundice is a prevalent disease that causes many complications, including kernicterus and even death. Previous studies have shown that clofibrate as an aryloxy isobutyric acid derivate can be effectively applied for the treatment of neonatal jaundice. Thus, this review was carried out to investigate the effects and mechanism of action of clofibrate on neonatal jaundice.

Methods: The keywords such as “Clofibrate” in combination with “Neonatal jaundice” or “Neonatal hyperbilirubinemia” or “Newborn Jaundice” were used to search for relevant publications indexed in the Institute for Scientific Information (ISI), Scopus, PubMed, and Google Scholar databases. Finally, after reviewing the studies, 24 papers were included in this study. **Results:** Results showed that the processes of albumin-bound bilirubin transfer to the hepatocytes, hepatic uptake, and storage via ligandin, hepatic conjugation via uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), conjugation into the bile via MRP2 represent the main action mechanism of clofibrate that turns it into the bilirubin conjugates and expels it from the bile. Besides, clofibrate has been shown to reduce the level of Total Serum Bilirubin (TSB) in infants even at a dosage of 25 mg/kg without leaving side effects. **Conclusions:** The results of this review revealed that clofibrate effectively reduces TSB in short-term usage and can even have a promising effect at the dosage of 25 mg/kg in full-term infants. Most studies have shown this property over a short period in term infants, and there is no evidence about long-term usage in this regard.

Keywords: Clofibrate, hyperbilirubinemia, neonatal jaundice, newborn jaundice

Introduction

Neonatal jaundice is one of the prevalent and life-threatening disorders in neonates.^[1] Neonatal jaundice is prevalent among up to 80% of premature infants and 60% of term infants.^[2,3] This disease develops during the first few days of birth and is caused by several factors such as uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), polymorphism, low birth weight, small for gestational age, neonatal sepsis, hematoma absorption, maternal-fetal ABO blood group incompatibility, metabolic diseases, liver diseases, etc.^[4] If it isn't treated in due time, it will result in dangerous and sometimes permanent complications such as neurological disorders, cerebral palsy, auditory nerve damage, chore athetoid, and bilirubin encephalopathy,^[5,6] and interferes with maternal-infant emotional interaction and breastfeeding.^[7] Additionally, this multi-risk factor disease is considered as a reason for most cases of newborn hospitalization imposing significant health

burdens in low-income and middle-income countries.^[8]

The main mechanism of jaundice is based on the imbalance between bilirubin production and conjugation. Bilirubin in the form of unconjugated bilirubin is transferred in the blood. The liver changes bilirubin into a conjugated form which is expelled from the body along with bile.^[9] Very high levels of unconjugated bilirubin can cause kernicterus and consequently neurotoxic complications like cerebral palsy and deafness.^[10,11] So if the jaundice is not treated properly as soon as possible, then it causes a lot of complications.^[1] Currently, various treatments are applied for the treatment of neonatal jaundice in medical settings among which phototherapy is the mainstay of these methods.^[12] Although, phototherapy has low complications in short-term treatment, it causes squints and abnormal developmental performance in newborns,^[13] interference with maternal-infant interaction, imbalance in thermal environment and water loss, electrolyte disturbance hypocalcemia, the

Fathemeh Eghbalian, Ali Hasanpour-Dehkordi¹, Roya Raeisi

Department of Pediatric, Hamadan University of Medical Sciences, Hamadan, Iran, ¹Social Determinants of Health Research Center, School of Allied Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran

Address for correspondence:

Dr. Roya Raeisi, Pediatric Department, Hamadan University of Medical Sciences, Hamadan, Iran. E-mail: r_reisi2@yahoo.com

Access this article online

Website:

www.ijpvmjournal.net/www.ijpm.ir

DOI: 10.4103/ijpvm.IJPVM_407_20

Quick Response Code:



How to cite this article: Eghbalian F, Hasanpour-Dehkordi A, Raeisi R. The effects of clofibrate on neonatal jaundice: A systematic review. *Int J Prev Med* 2022;13:3.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

disorder of circadian rhythms, as well as the development of the bronze baby syndrome.^[14-16] Besides, the health care providers must consider a set of items such as different wavelengths, total doses, intensities, and commencement threshold for achieving the best effectiveness and safety.^[17] Therefore, in addition to the phototherapy administered, as the current treatment to reduce the complications and treatment duration, other treatments, such as medication therapy should be considered. Therefore, the increasing desire to use drugs has been developed as an adjunct therapy. On the other hand, there is limited strong evidence about the use of pharmacotherapy such as clofibrate, human albumin, intravenous immunoglobulin, herbal therapy, ursodeoxycholic acid, and phenobarbital treatment in neonatal jaundice.^[12,18-21] Clofibrate is an aryloxyisobutyric acid derivative used in the treatment of hypertriglyceridemia and dyslipidemia.^[13] However, previous studies showed that clofibrate is effective in the treatment of neonatal jaundice.^[14,22] Therefore, this study was conducted to investigate the effects and mechanism of clofibrate action on neonatal jaundice.

Materials and Methods

To conduct this study, the keywords of interest were searched using EndNote software. The keywords included “Clofibrate” in combination with “Neonatal jaundice” or “Neonatal hyperbilirubinemia” or “Newborn Jaundice” that were used to search for relevant publications indexed

in the Institute for Scientific Information (ISI), Scopus, and PubMed databases. (For ISI and PubMed databases, keywords were searched by EndNote software.)

Given the insufficiency of the studies in the ISI and PubMed databases, the Google scholar database was searched. Among 862 results obtained concerning the mentioned keywords, 6 papers (except duplications) were added to the bank of the study. A standard form was designed consisting of items such as author, the title or purpose of the study, intervention, gestational age, birth weight, age at enrolment (day), Total Serum Bilirubin (TSB) at admission, clofibrate dosage (mg/kg), side effects (at hospitalization period and follow-up), outcomes (including the mean TSB, duration of phototherapy, and duration of hospitalization), journal name and article number. The full text of the papers matched the purpose of the study was recorded in the form and entered into the study with agreement of co-authors. A search was conducted by two separate researchers. The inclusion criteria were clinical trials performed on neonatal jaundice, as well as the studies that showed positive effects on neonatal jaundice. The papers which had non-positive effects, full texts of which were not accessible, review papers, non-English or non-Persian language papers, and those which were not related to the aim of this study were excluded after all the authors reached an agreement. Finally, 24 papers were included in the study [Figure 1].

For quality assessment, the protocol of RCTs was considered and the methodological quality of the primary




Figure 1: Flowchart of the study design (This flowchart illustrates how the papers were selected for final analysis.)




Figure 2: Bilirubin clearance mechanism of clofibrate in the liver

Table 1: The effects of clofibrate treatment on neonatal jaundice

References	Gestational age	Birth weight (kg)	Age at enrolment (day)	TSB at admission (mg/dl)	Direct and indirect bilirubin (mg/dl)	Clofibrate dose (mg/kg)	Side effects	TSB level (mg/dl)	Direct and indirect bilirubin (mg/dl)	Duration of phototherapy	Duration of hospitalization	Outcome*
Mohammadzadeh <i>et al.</i> ^[23]	Full-term (37-41 weeks of gestation)	3260±481	9±4	23.33±3.36	0.92±0.52 (Direct)	100	No	Reduced (After 12, 24, and 48 h)	No change reported for direct bilirubin	Reduced	-	-
Zahedpasha <i>et al.</i> ^[24]	Not reported	3110.8±453.9	6.02±2.09	17/85±2.09	0.79±0.12 (Direct)	100	No	Reduced (After 48 and 72 h)	No change reported for direct bilirubin	-	Reduced	Reduced
Eghbalian <i>et al.</i> ^[14]	Full-term	>2500	Majority 2-3	20.85±3.6	20.35±3.5 (Indirect)	100	No	Reduced (After 12 and 24 h)	Reduced for indirect bilirubin (After 12 and 24h)	Reduced	Reduced	Reduced
Mostehi <i>et al.</i> ^[25]	Full-term	2543±548	5.2±1.9	17.63±1.4	0.46±0.20 (Direct)	25/50	No	Reduced (After 12 and 24 h)	-	Reduced	-	-
Zahedpasha <i>et al.</i> ^[26]	Full-term	3133±456	6.0±2.9	17.85±2.09	0.79±0.11 (Direct)	100	No	Reduced (After 48 and 72 h)	No change reported for direct bilirubin	-	Reduced	Reduced
Badeli <i>et al.</i> ^[27]	Full-term	3171±278	5.3±1.8	18.4±1.6	-	100	No	Reduced (After 12, 24, and 36 h)	-	Reduced	Reduced	Reduced
Mohammadzadeh <i>et al.</i> ^[28]	Preterm (31.5±1.5 weeks of gestation)	1369±201	31.48±1.52	5.9±2.4	-	100	No	Reduced (After 24 h)	-	Reduced	-	-
Zahedpasha <i>et al.</i> ^{[29]**}	Full-term	3258±479	18.0±1.9	5.1±2.3	0.78±0.18 (Direct)	100	No	Reduced (After 16, 24, and 48 h)	No change for direct bilirubin	Reduced	Reduced	Reduced
Ghotbi <i>et al.</i> ^[30]	Full-term	3211.5±425	4.2±0.15	17.4±0.93	-	100	No	Reduced (After 12, 24, and 48 h)	-	-	Reduced	Reduced
Mohammadzadeh <i>et al.</i> ^[31]	Preterm (31.5±1.5 weeks of gestation)	2114±328 (Low birth weight)	9.2±5.4	21.1±5.2	0.51±0.26 (Direct)	100	No	No change	No change	Reduced	-	-
Sakha <i>et al.</i> ^[32]	Preterm (34-37 weeks of gestation)	2359±535	6.1±2.9	19.8±2.4	0.82±0.41 (Direct)	100	No	Reduced (After 48 h)	-	Reduced	Reduced	-
Sharafi <i>et al.</i> ^[33]	Full-term	3129±431	6.7±2.9	17.3±1.5	-	50	No	Reduced (After 24 and 48 h)	-	Reduced	-	-
Alipour <i>et al.</i> ^[34]	Full-term	3245±189	6±2.56	-	-	100	No	Reduced (After 24 h)	-	Reduced	-	-
Eghbalian <i>et al.</i> ^[35]	-	-	-	3.31±1.84	-	50/25	No	Reduced (After 12, 24, and 36 h)	-	Reduced	Reduced	Reduced
Fallah <i>et al.</i> ^[36]	Full-term	3197±370	4.85±1.96	19.52±2.64	-	50	No	Reduced (After 12, 24, and 48h)	-	Reduced	Reduced	Reduced
Habibi <i>et al.</i> ^[22]	Full-term	3081±319	3.25±1.04	20.65±2.41	0.45±0.48 (Direct)	100	-	Reduced (After 24 and 48 h)	-	Reduced	Reduced	-

Contd...

Table 1: Contd...

References	Gestational age	Birth weight (kg)	Age at enrolment (day)	TSB at admission (mg/dl)	Direct and indirect bilirubin (mg/dl)	Clofibrate dose (mg/kg)	Side effects	Outcome*		
								TSB level (mg/dl)	Direct and indirect bilirubin (mg/dl)	Duration of phototherapy hospitalization
Ahadi <i>et al.</i> ^[37]	Full-term	2500-4000	4.06±4.04	17.94±1.01	-	100	No	Reduced (After 24 and 72 h)	-	Reduced
Hamidi <i>et al.</i> ^[38]	Full-term	-	-	17.5±1.4	-	100	No	Reduced (After 12, 24, 48, and 72 h)	Reduced	Reduced
Poursakha <i>et al.</i> ^[39]	Near term (35 weeks of gestation)	2360±0.53	6.11±2.88	19.88±2.30	-	100	No	Reduced (After 48 h)	Reduced	-
Zahed Pasha <i>et al.</i> ^[40]	Full-term	2500-4000	-	2.05±0.06 (Umbilical cord bilirubin)	-	50	-	No change	-	-
Nourishadkam <i>et al.</i> ^[41]	Full-term	3240±380	6.12±2.48	16.49±2.64	-	100	No	Reduced (After 24 h)	-	-
Alosy ^[42]	Full-term	2500-4000	-	-	-	100	No	Reduced (After 24 and 69 h)	Reduced	Reduced
Kumar <i>et al.</i> ^[43]	Full-term	2780±253.5	4.05±1.48	18.3±2.05	-	50	No	Reduced (After 48 h)	Reduced	-

*Outcomes considered based on comparing the P between control and treatment groups. **Neonates were affected by glucose-6-phosphate dehydrogenase (G6PD) deficiency

studies was assessed including research design, study sample, participation rates, sources of bias, data collection, follow-up or attrition rates, and data analysis. The studies with the minimum clinical trials requirements were included in the study.

Results

Finally, 24 papers were found to meet the inclusion criteria and were selected for the study. Most important variables influencing the outcome of the studies and clofibrate treatment are presented in Table 1.

Discussion

This study was conducted to investigate the effects and action mechanism of clofibrate on neonatal jaundice. Clofibrate modulates the gene involved in lipid homeostasis^[44] and as an aryloxyisobutyric acid derivate can stimulate peroxisomeproliferator-activated receptors, as a result of which the conjugation with glucuronic acid is catalyzed by UGT1A1.^[45,46] Eventually, bilirubin conjugates are excreted into the bile through the canalicular ATP-dependent transporter MRP2. Taken together, clofibrate increases the excretion of albumin-bound bilirubin through enhancing the enzymatic steps in hepatocytes^[47] [Figure 2].

Besides, clofibrate increases the stimulation of glucuronosyltransferase and augments bilirubin conjugation and excretion, causing a significant increase in the bilirubin clearance and reduction of unconjugated hyperbilirubinemia.^[48] Therefore, these changes also reduce the duration of phototherapy and hospitalization in neonates and diminish the complications attributed to them. Although clofibrate acts as an antilipemic drug and causes several complications (such as vomiting, nausea, gastrointestinal problems, loose stools, leucopenia, transient cholestasis, muscle cramping, fatigue, pruritus, alopecia, renal failure, abnormal liver function)^[16,49-54] the reviewed studies showed that, the dose of 25-100 mg/kg and short-time administration of clofibrate has not exerted any complication during the treatment and follow-up periods. Lipid and unconjugated bilirubin can conjoint each other and bond to the albumin. Therefore, changes in bilirubin amounts must be adjusted by considering the lipid profile alteration. In this regard, lipids are one of the most important macronutrients, which are necessary for cell growth and development in newborns, so the long-term administration of clofibrate can impair organ development and growth.^[55,56]

In the reviewed studies, complications were mostly evaluated by clinical observations which could be considered as a limitation of the clinical studies. Thus, it is recommended to perform laboratory tests and biochemistry examinations (according to the side effects) in future studies to obtain more valuable results. A high degree of heterogeneity among the trials resulted from different TSB levels at baseline,

limitation in geological regions (the majority of the trials were carried out in Asia which conceals the effects of genetic factors), lack of using the placebo, and consequently lack of blinding in the control group and unclear allocation was among other limitations of the reviewed studies. On the other hand, hemolytic disease (ABO incompatibility of Rh) and congenital anomaly of infants were considered as exclusion criteria or there was rare number of studies conducted in this area. Therefore, conducting such studies can indicate clear results and address its optimal therapeutic dose in infants with hemolytic diseases.^[57]

Conclusion

The results of this review revealed that clofibrate effectively reduces TSB in short-term usage and can even have a promising effect at the dosage of 25 mg/kg in full-term infants. Larger RCTs (complying with all principles of the design) along with longer follow-up and considering hemolytic disease and blood transfusion are needed to elaborate more on the issue.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Received: 21 Jul 20 **Accepted:** 22 Dec 20

Published: 19 Jan 22

References

- Ullah S, Rahman K, Hedayati M. Hyperbilirubinemia in neonates: Types, causes, clinical examinations, preventive measures and treatments: A narrative review article. *Iran J Public Health* 2016;45:558-68.
- Rennie J, Burman-Roy S, Murphy MS. Neonatal jaundice: Summary of NICE guidance. *BMJ* 2010;340:c2409.
- Porter ML, Dennis BL. Hyperbilirubinemia in the term newborn. *Am Fam Phys* 2002;65:599-606.
- Babaei H, Parham S. Risk factors of severe hyperbilirubinemia in neonates undergoing exchange transfusion in Imam Reza Hospital Kermanshah-Iran, during 2012 to 2016. *Int J Pediatr* 2018;6:8061-72.
- Davutoglu M, Garipardic M, Guler E, Karabiber H, Erhan D. The etiology of severe neonatal hyperbilirubinemia and complications of exchange transfusion. *Turk J Pediatr* 2010;52:163-6.
- Das S, van Landeghem FKH. Clinicopathological spectrum of bilirubin encephalopathy/kernicterus. *Diagnostics (Basel)* 2019;9:24.
- Waite WM, Taylor JA. Phototherapy for the treatment of neonatal jaundice and breastfeeding duration and exclusivity. *Breastfeed Med* 2016;11:180-5.
- Romero HM, Ringer C, Leu MG, Beardsley E, Kelly K, Fesinmeyer MD, *et al.* Neonatal jaundice: Improved quality and cost savings after implementation of a standard pathway. *Pediatrics* 2018;141:e20161472.
- Mitra S, Rennie J. Neonatal jaundice: Aetiology, diagnosis and treatment. *Br J Hosp Med (Lond)* 2017;78:699-704.
- Rasul CH, Hasan MA, Yasmin F. Outcome of neonatal hyperbilirubinemia in a tertiary care hospital in Bangladesh. *Malays J Med Sci* 2010;17:40-4.
- Slusher TM, Zamora TG, Appiah D, Stanke JU, Strand MA, Lee BW, *et al.* Burden of severe neonatal jaundice: A systematic review and meta-analysis. *BMJ Paediatr Open* 2017;1:e000105-e.
- Wan A, Mat Daud S, Teh SH, Choo YM, Kutty FM. Management of neonatal jaundice in primary care. *Malays Fam Phys* 2016;11:16-9.
- Drew JH, Marriage K, Bayle VV, Bajraszewski E, McNammara JM. Phototherapy. Short and long-term complications. *Arch Dis Child* 1976;51:454-8.
- Eghbalian F, Pourhossein A, Zandevakili H. Effect of clofibrate in non-hemolytic indirect hyperbilirubinemia in full term neonates. *Indian J Pediatr* 2007;74:1003-6.
- Peinado-Acevedo JS, Chacon-Valenzuela E, Rodriguez-Moncada LL. [Bronze baby syndrome, an unpredictable complication of phototherapy: A case report]. *Biomedica* 2018;38:15-8.
- Xiong T, Qu Y, Cambier S, Mu D. The side effects of phototherapy for neonatal jaundice: What do we know? What should we do? *Eur J Pediatr* 2011;170:1247-55.
- Woodgate P, Jardine LA. Neonatal jaundice: Phototherapy. *BMJ Clin Evid* 2015;2015:0319.
- Monsef A, Eghbalian F, Rahimi N. Comparison of purgative manna drop and phototherapy with phototherapy treatment of neonatal jaundice: A randomized double-blind clinical trial. *Osong Public Health Res Perspect* 2019;10:152.
- Raeisi R, Heidari-Soureshjani S, Asadi-Samani M, Luther T. A systematic review of phytotherapies for newborn jaundice in Iran. *Int J Pharm Sci Res* 2017;8:1953-8.
- Gharehbaghi MM, Sani AM, Refeey M. Evaluating the effects of different doses of ursodeoxycholic acid on neonatal jaundice. *Turk J Pediatr* 2020;62:424-30.
- Honar N, Saadi EG, Saki F, Pishva N, Shakibzad N, Teshnizi SH. Effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy. *J Pediatr Gastroenterol Nutr* 2016;62:97-100.
- Habibi M, Mahyar A, Ayazi P, Ahmadabadi F, Javadi A. The effect of clofibrate on hyperbilirubinemia of term neonates. *Acta Med Iran* 2012;50:21-5.
- Mohammadzadeh A, Farhat A, Iranpour R. Effect of clofibrate in jaundiced term newborns. *Indian J Pediatr* 2005;72:123-6.
- Zahedpasha Y, Naderi S, Ahmadpour M. Effect of clofibrate plus phototherapy on bilirubin concentration of. *Hormozgan Medical Journal*.2006;10:207-12.
- Moslehi M, Pishva N. Determination of effect of low dose vs moderate dose clofibrate on decreasing serum bilirubin in healthy term neonates. *Iran J Pediatr* 2007;17:108-12.
- Zahedpasha Y, Ahmadpour-Kacho M, Hajiahmadi M, Naderi S. Effect of clofibrate in jaundiced full-term infants: a randomized clinical trial. *Arch Iran Med* 2007;10:349-53.
- Badeli HR, Sharafi R, Sajedi SA. The effect of clofibrate on neonatal hyperbilirubinemia in uncomplicated jaundice. *Iran J Pediatr* 2008;18:20-4.
- Mohammadzadeh A, Sh FA, Jafarzadeh M, Mirzarahimi M, Esmaeli H, Amiri R. Prophylactic effect of clofibrate in low birth weight neonates hyperbilirubinemia. *J Chin Clin Med* 2008;3.
- Zahedpasha Y, Ahmadpour-Kacho M, Hajiahmadi M, Naderi S, Kamali AA. Efficacy of clofibrate on severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency (a randomized clinical trial). *Southeast Asian J Trop Med Public Health* 2008;39:557-61.
- Ghotbi F, Tghiloo M, Gashb A. The effect of clofibrate on neonatal jaundice. *Pejoughesh dar Pezeshki (Research in*

- Medicine). 2009;33:31-4.
31. Mohammadzadeh A, Farhat AS, Amiri R, Esmaely H, Bagheri S. Treatment effect of clofibrate in jaundiced low birth weight neonates. *International Journal of Hematology and Oncology*. 2009;30:100-5.
 32. Sakha SH, Gharehbaghi M, Rahbani M. The effect of clofibrate with phototherapy in late pre-term newborns with non-hemolytic jaundice. *Indian J Med Sci* 2009;63:174-9.
 33. Sharafi R, Mortazavi Z, Sharafi S, Parashkoush RM. The effect of clofibrate on decreasing serum bilirubin in healthy term neonates under home phototherapy. *Iran J Pediatr* 2010;20:48-52.
 34. Alipour AA, Babae H, Barghaei A, Hashemian AH, Azizi M. The effect of clofibrate and phototherapy on physiological jaundice in term newborns. *Behbood* 2011;15:233-7.
 35. Eghbalian F, Ghomi Tabataei N, Aalam, and A.R. Monsef. "Effect Of Different Doses Of Clofibrate On Neonatal Jaundice." *Annals of Military and Health Sciences Research* 2011;9:192-8.
 36. Fallah R, Islami Z, Lotfi SR. Single dose of 50 mg/kg clofibrate in jaundice of healthy term neonates: Randomised clinical trial of efficacy and safety. *Indian J Pediatr* 2012;79:194-7.
 37. Ahadi A, Mirzarahimi M, Ahmadabadi F, Tavasoli A, Parvaneh N. Comparison of the efficacy of clofibrate with phenobarbital in decreasing neonatal hyperbilirubinemia. *Iran J Neonatol* 2013;4:13-9.
 38. Hamidi M, Zamanzad B, Mesripour A. Comparing the effect of clofibrate and phenobarbital on the newborns with hyperbilirubinemia. *Excli J* 2013;12:75-8.
 39. Poursakha SH, Gharehbaghi MM, Rahbani ME. The effect of clofibrate in near term newborns with non hemolytic jaundice. *Int J Med Med Sci* 2013;5:251-4.
 40. Zahed Pasha Y, Mahdipour S, Ahmadpour-Kacho M, Bijani A, Taheri M. Preventive effect of clofibrate on neonatal hyperbilirubinemia. *Caspian J Pediatr* 2015;1:5-8.
 41. Nourishadkam M, Mohammadi MJ, Nasiriani K. Evaluation of the effect of oral clofibrate intake on neonatal total serum bilirubin: A randomized clinical trial. *Iranian Journal of Neonatology IJN*. 2016;7:5-8.
 42. Alosy BDM. Benefit of Clofibrate on indirect hyperbilirubinemia in newborn. *Al-Mustansiriyah J Pharm Sci* 2017;17:134-9.
 43. Kumar P, Adhisivam B, Bhat BV. Clofibrate as an adjunct to phototherapy for unconjugated hyperbilirubinemia in term neonates. *Indian J Pediatr* 2017;84:763-7.
 44. Bhutani VK. Editorial: Building evidence to manage newborn jaundice worldwide. *Indian J Pediatr* 2012;79:253-5.
 45. Mancuso C. Bilirubin and brain: A pharmacological approach. *Neuropharmacology* 2017;118:113-23.
 46. Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. *World J Gastroenterol* 2013;19:6398-407.
 47. Cuperus FJ, Hafkamp AM, Hulzebos CV, Verkade HJ. Pharmacological therapies for unconjugated hyperbilirubinemia. *Curr Pharm Des* 2009;15:2927-38.
 48. Gholitabar M, McGuire H, Rennie J, Manning D, Lai R. Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinaemia. *Cochrane Database Syst Rev* 2012;12:CD009017.
 49. Brun S, Carmona MC, Mampel T, Vinas O, Giralt M, Iglesias R, *et al.* Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: A potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth. *Diabetes* 1999;48:1217-22.
 50. Steiner A, Weisser B, Vetter W. A comparative review of the adverse effects of treatments for hyperlipidaemia. *Drug Saf* 1991;6:118-30.
 51. Erkul I, Yavuz H, Ozel A. Clofibrate treatment of neonatal jaundice. *Pediatrics* 1991;88:1292-4.
 52. Pokroy N, Ress S, Gregory MC. Clofibrate-induced complications in renal disease: A case report. *S Afr Med J* 1977;52:806-8.
 53. Pierides AM, Alvarez-Ude F, Kerr DN. Clofibrate-induced muscle damage in patients with chronic renal failure. *Lancet* 1975;2:1279-82.
 54. Eghbalian F, Monsef F, Alam Ghomi N, Monsef A. Effect of low versus moderate dose of clofibrate on serum bilirubin in healthy term neonates with indirect hyperbilirubinemia. *Iran J Med Sci* 2013;38:349-50.
 55. Torkaman M, Saburi A. What is important about the effect of clofibrate on neonatal hyperbilirubinemia? *Acta Med Iran* 2013;51:139-40.
 56. Martinez N, White V, Kurtz M, Higa R, Capobianco E, Jawerbaum A. Activation of the nuclear receptor PPARalpha regulates lipid metabolism in foetal liver from diabetic rats: Implications in diabetes-induced foetal overgrowth. *Diabetes Metab Res Rev* 2011;27:35-46.
 57. Torabi Z, Eskandarzadeh A, Ahmadiafshar A. The effect of clofibrate with phototherapy on full-term newborns with non-hemolytic jaundice. *Iran Red Crescent Med J* 2013;15:285-6.